Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned, research-driven specialty biopharmaceutical group headquartered in Saint-Prex, Switzerland. Founded in 1950, the company has established itself as a global leader in reproductive medicine and maternal health, while expanding its presence into specialty areas such as gastroenterology, urology, uro-oncology, and orthopaedics. The company is at the forefront of innovative therapeutic modalities, including the development of the first FDA-approved intravesical gene therapy for bladder cancer (Adstiladrin) and the first FDA-approved fecal microbiota-based treatment (Rebyota). Ferring operates in over 50 countries and markets its products in more than 100 countries, investing approximately 15% of its annual revenue back into research and development.